The increasing number of cancer survivors has highlighted the problem of tumour dormancy, which can lead to relapse. Preclinical models and initial clinical trials are paving the way to address how best to treat long-term cancer survivors to minimize the risk of late cancer recurrence.
- Paul E. Goss
- Ann F. Chambers
